FASEB Conference: Genome Engineering: Research and...
CMN Briefs
May. 7, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Edity Therapeutics
Company Type: Therapeutics
Main focus: Immune cell engineering to deliver therapeutics to diseased cells
Company stage: Pre-clinical
Diseases: Cancer and genetic disease
Genome-editing tool:
Funding stage: Pre-Seed
Location: Rehovot, HaMerkaz, Israel
Website: https://edity-tx.com/
Pipeline:
Partners:
Edity Therapeutics is developing a new therapeutic platform that takes advantage of the natural ability of immune cells to release cargo (e.g. lytic payloads) within the cells they dock with. Edity Therapeutics plans to swap the natural cargo with a therapeutic payload which can then be released into the target cells.
